Higher vitamin B12 level at Parkinson's disease diagnosis is associated with lower risk of future dementia.
Cyanocobalamin
Dementia
Parkinson's disease
Vitamin B12
Journal
Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
10
12
2019
revised:
10
03
2020
accepted:
14
03
2020
pubmed:
24
3
2020
medline:
30
3
2021
entrez:
24
3
2020
Statut:
ppublish
Résumé
To determine whether vitamin B12 level at Parkinson's disease (PD) diagnosis predicts time to develop dementia. We utilized a population-based cohort of Parkinsonism patients to examine the relationship between serum vitamin B12 at the time of PD diagnosis and dementia risk. Receiver operating curves were calculated for vitamin B12 cutoffs maximizing sensitivity and specificity for determining who developed dementia. Time from Parkinsonism diagnosis to dementia, death, or censoring was calculated utilizing Kaplan-Meier analysis and Cox-proportional hazard models. PD patients who did not develop dementia had higher baseline levels of vitamin B12 at PD diagnosis (648.5 ng/L vs 452 ng/L, p < 0.05) than those who developed dementia. Dementia risk was significantly lower in the 3rd tertile compared with 2nd tertile and trended towards significance compared to the 1st tertile. Each 100 unit increase in vitamin B12 level had a hazard ratio of 0.31 (95% CI 0.44-0.95) for future dementia (p < 0.05). Vitamin B12 cutoff of <587 ng/L was 87% sensitive and 70% specific (AUC 0.79, 95% CI 0.60-0.98) distinguishing patients with dementia. PD patients with vitamin B12 levels <587 ng/L were 5.4 times more likely to develop dementia, with 50% having dementia within 5 years of PD diagnosis compared with 11% in those with a vitamin B12 level of ≥587 ng/L (p < 0.05). Higher levels of serum vitamin B12 at PD diagnosis correlate with lower risk of future dementia. The role of vitamin B12 in the development of dementia among PD patients deserves further evaluation.
Identifiants
pubmed: 32203914
pii: S1353-8020(20)30065-1
doi: 10.1016/j.parkreldis.2020.03.009
pii:
doi:
Substances chimiques
Vitamin B 12
P6YC3EG204
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19-22Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of competing interest SJ McCarter, C Stang, T Pierpaolo, F Ali, JR Bower and R Savica report no disclosures. MM Mielke receives funding from the National Institutes of Health/National Institute on Aging and unrestricted research grants from Biogen. R Savica receives funding from the National Center for the Advancing Translational Sciences and Acadia Pharmaceuticals.